Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy

January 20, 2025 |  

Discover the key takeaways from OPEN Health’s latest whitepaper: “The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy.”

IRA whitepaper_OPEN Health

Discover the key takeaways from OPEN Health’s latest whitepaper The Potential Impact of the New Presidential Administration on the Future of the Inflation Reduction Act and Broader Healthcare Policy:

  • Review of President Trump’s healthcare policies during his first term: Attempts to repeal the Affordable Care Act (ACA), drug pricing initiatives, and Medicare and Medicaid policies.
  • A look into the future of the Inflation Reduction Act (IRA) and broader healthcare policy in the US: The potential impact of the incoming administration on the healthcare provisions of the IRA and other statements by President Trump focused on healthcare policy.

Read the full whitepaper to understand how these developments could influence healthcare decision-making and strategy. View the whitepaper here.

Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. Together we can unlock possibilities. For information about OPEN Health’s services and how we could support you, please get in touch. 

This content was provided by OPEN Health

Company Details

OPEN Health

OPEN Health

Email
Website

 Latest Content from  OPEN Health 

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials – Part 2: Clinical Benefit and Patient Preference”, has sparked our interest….

Spotlight interview: 15 minutes on insights and market research in pharma

Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications…

Patient journey mapping: exploring the clinical and the emotional journey

By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the…

OPEN Health announces the integration of Pharmerit International into the group

OPEN Health has today announced the integration of Pharmerit International, a global leader in health economics and outcomes research (HEOR), into its group of companies.

OPEN Health mobilised to support outcomes with gene and other advanced therapies

Harnessing the power of collaborations to bring real insights and improve outcomes

Spotlight interview: 15 minutes on PR in pharma

Vicky Bramham, Managing Director, OPEN Health takes 15 minutes to answer some key questions on PR discipline.

OPEN Health PBC recognised as No. 1 independent creative agency

We’re No.1! PMLive have named OPEN Health Patient & Brand Communications as the no.1 independent creative healthcare agency. The aim of the PMLive Top 10 lists is to highlight those…

Spotlight interview: 15 minutes on medical and scientific writing

Rob Pilbrow, Global Managing Director, Medical Writing, OPEN Health takes 15 minutes to answer some key questions on scientific writing

Spotlight interview: 15 minutes on healthcare advertising

Marie Little, Managing Director, OPEN Health Patient & Brand Communications takes 15 minutes to answer some key questions on healthcare advertising